We are honored to announce our participation in the PCR Tokyo Valves 2025 (February 7-9, Tokyo), a premier global forum for cardiac valve innovation. As an OECD GLP-certified leader in preclinical large animal studies, GoldenWing Medical brings unparalleled expertise in cardiac valve research, validated by globally recognized reports accepted by regulatory authorities worldwide.
Why Partner with Us?
✅ Rigorous Compliance: Our OECD GLP-certified protocols ensure data integrity for FDA, CE, NMPA, and other international submissions .
✅ Specialized Expertise: Over 15 years of experience in cardiac valve, orthopedics, and interventional device testing, supported by 200+ medical professionals with advanced degrees .
✅ Global-Focused Solutions: Tailored strategies to align with Japan’s healthcare standards and collaborative opportunities in advancing minimally invasive therapies like TAVR and TEER, which are rapidly growing in Asia-Pacific markets .
Join Us in Shaping the Future of Cardiac Care
To Japanese medical innovators: Let’s collaborate to accelerate device development with reliable data, seamless regulatory alignment, and cutting-edge preclinical models. Explore how our 18,000㎡ lab and surgical training programs can support your goals!
